The small molecule axl inhibitor BGB324 shows activity against T315I-mutated and BCR-ABL1 wt chronic myeloid leukemia

被引：0

作者：

Erdmann, R. ^{[1
,2
]}

Jorgensen, H. ^{[3
]}

Ben-Batalla, I. ^{[1
,2
]}

Kruse, N. ^{[1
,2
]}

Micklem, D. ^{[4
]}

von Amsberg, G. ^{[1
]}

Schafhausen, P. ^{[1
]}

Schultze, A. ^{[1
]}

Wroblewski, M. ^{[1
,2
]}

Binder, M. ^{[1
]}

Cubas-Cordova, M. ^{[1
,2
]}

Hadlich, T. ^{[1
]}

Janing, M. ^{[1
,2
]}

Sawall, S. ^{[1
,2
]}

Witzke, V. ^{[1
,2
]}

Lorens, J. ^{[4
]}

Allan, E. ^{[3
]}

Mukherjee, L. ^{[3
]}

Morrison, H. ^{[3
]}

Cassells, J. ^{[3
]}

Koerger, N. ^{[5
]}

Lorens, J. B. ^{[6
]}

Clark, R. ^{[7
]}

Koschmieder, S. ^{[8
]}

Vandenberghe, P. ^{[9
]}

Bruemmendorf, T. ^{[8
]}

Hochhaus, A. ^{[10
]}

Carmeliet, P. ^{[11
]}

Holyoake, T. ^{[3
]}

Pantel, K. ^{[2
]}

Bokemeyer, C. ^{[1
,12
]}

Loges, S. ^{[1
,2
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Med Clin 2, Hamburg, Germany

[2] Dept Tumor Biol, Hamburg, Germany

[3] Univ Glasgow, Paul OGorman Leukemia Res Ctr, Coll Med Vet & Life Sci, Glasgow, Lanark, Scotland

[4] BerGenBio AS, Jonas Lies, Bergen, Norway

[5] Univ Med Ctr Hamburg Eppendorf, Ctr Oncol, Bone Marrow Transplantat Unit, Hamburg, Germany

[6] Univ Bergen, Dept Biomed, Bergen, Norway

[7] Univ Liverpool, Royal Liverpool Univ Hosp, Liverpool L69 3BX, Merseyside, England

[8] Univ Klinikum RWTH Aachen, Aachen, Germany

[9] Katholieke Univ Leuven, Ctr Human Genet, Leuven, Belgium

[10] Univ Klinikum Jena, Klin Innere Med 2, Jena, Germany

[11] VIB, Lab Angiogenesis & Neurovasc Link, Vesalius Res Ctr, Leuven, Belgium

[12] Univ Med Ctr Eppendorf, Hubertus Wald Univ Canc Ctr, Dept Hematol & Oncol, Hamburg, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V935

引用

页码：309 / 309

页数：1

共 50 条

[21] Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K
Afsar Ali Mian
Isabella Haberbosch
Hazem Khamaisie
Abed Agbarya
Larissa Pietsch
Elizabeh Eshel
Dally Najib
Claudia Chiriches
Oliver Gerhard Ottmann
Oliver Hantschel
Ricardo M. Biondi
Martin Ruthardt
Jamal Mahajna
Annals of Hematology, 2021, 100 : 2023 - 2029
[22] Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 T315I-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP)
Qian, Jiang
Shi, Dayu
Li, Zongru
Hou, Yue
Hu, Yu
Li, Weiming
Liu, Xiaoli
Xu, Na
Song, Yongping
Zhang, Gongli
Meng, Li
Hong, Zhenya
Liu, Bingcheng
Li, Yan
Chen, Suning
Xue, Mengxing
Zhu, Huanling
Li, He
Du, Xin
Lou, Jin
Zhang, Xiaohan
Liang, Yang
Dai, Yujun
Chen, Zi
Niu, Qian
Men, Lichuang
Yang, Dajun
Zhai, Yifan
Huang, Xiaojun
BLOOD, 2021, 138
[23] Efficacy and Safety of Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor Targeting the Myristoyl-Binding Site, in Patients with Chronic Myeloid Leukemia (CML) Carrying the T315I Mutation
Deininger, Michael W.
Rea, Delphine
Lang, Fabian
Kim, Dong-Wook
Cortes, Jorge E.
Hughes, Timothy P.
Minami, Hironobu
Breccia, Massimo
DeAngelo, Daniel J.
Hochhaus, Andreas
Talpaz, Moshe
Goh, Yeow Tee
Le Coutre, Philipp D.
Etienne, Gabriel
Sondhi, Manu
Mishra, Kaushal
Aimone, Paola
Mauro, Michael J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S289 - S290
[24] Novel Inhibitors of T315I Mutant BCR-ABL1 Tyrosine Kinase for Chronic Myeloid Leukemia Disease Through Fragment-Based Drug Design
Anindita, Satya
Marnolia, Atika
Putra, Hersal Hermana
Haikal, Muhammad Chandra
Tambunan, Usman Sumo Friend
BIOINFORMATICS RESEARCH AND APPLICATIONS, ISBRA 2018, 2018, 10847 : 185 - 190
[25] Bestinib, a novel Bcr-Abl inhibitor for Chronic Myeloid Leukemia, inhibits a wide array of Bcr-Abl mutants including imatinib resistant T315I mutant
Gupta, Pranav
Yang, Ke
Wang, Fang
Wang, Xiaokun
Kathawala, Rishil J.
Fu, Liwu
Chen, Zhe Sheng
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S100 - S100
[26] MK-0457, a novel multikinase inhibitor, inhibits BCR-ABL activity in patients with chronic myeloid leukemia (CML) and acute lymphocytic leukemia (ALL) with the t315I BCR-ABL mutation.
Bergstrom, Donald A.
Clark, Jason B.
Xiao, Alan
Griffiths, Matthew
Falcon, Susannah
Pollard, John
Freedman, Steven J.
Giles, Francis
BLOOD, 2006, 108 (11) : 192A - 192A
[27] PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia
Gupta, Pranav
Kathawala, Rishil J.
Wei, Liuya
Wang, Fang
Wang, XiaoKun
Druker, Brian J.
Fu, Li-Wu
Chen, Zhe-Sheng
CANCER LETTERS, 2016, 383 (02) : 220 - 229
[28] HS-438, a new inhibitor of Imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia
Yun, Sun-Mi
Jung, Kyung Hee
Kim, Soo Jung
Fang, Zhenghuan
Son, Mi Kwon
Yan, Hong Hua
Lee, Hyunseung
Kim, JinHee
Shin, Sanghye
Hong, Sungwoo
Hong, Soon-Sun
CANCER LETTERS, 2014, 348 (1-2) : 50 - 60
[29] UM-9107: A selective wild-type and T315I Bcr-Abl inhibitor with in vivo activity against chronic myelogenous leukemia
Phadke, Sameer
Lopez-Barcons, Lluis
Johnson, Taylor K.
Lachacz, Eric J.
Merajver, Sofia D.
Soellner, Matthew B.
CANCER RESEARCH, 2019, 79 (13)
[30] Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34+ cells of patients with de novo chronic myeloid leukemia
Jurcek, Tomas
Razga, Filip
Mazancova, Petra
Musilova, Milena
Dvorakova, Dana
Borsky, Marek
Zackova, Daniela
Dobesova, Blanka
Semerad, Lukas
Mayer, Jiri
Racil, Zdenek
LEUKEMIA & LYMPHOMA, 2014, 55 (08) : 1915 - 1917

← 1 2 3 4 5 →